AVBP (ArriVent BioPharma) ROCE %: -58.41% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVBP ArriVent BioPharma Inc AVBP
12 GF Score
Price $32.54
! 2 Warning Signs
View Full Analysis

What is ArriVent BioPharma ROCE %?

ArriVent BioPharma AVBP -3.27% 12 ROCE % is -58.41% as of Mar. 2026. GuruFocus rates AVBP with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ArriVent BioPharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -58.41%.

ArriVent BioPharma  (NAS:AVBP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ArriVent BioPharma ROCE % Related Terms

ArriVent BioPharma ROCE % Historical Data

* Premium members only.

The historical data trend for ArriVent BioPharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ArriVent BioPharma ROCE % Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
0.00 -34.22 -45.77 -46.10 -62.86

ArriVent BioPharma Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -116.07 -59.46 -55.24 -50.73 -58.41
AVBP
12GF Score
ArriVent BioPharma Inc AVBP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ArriVent BioPharma ROCE % Calculation

ArriVent BioPharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-177.534/( ( (274.942 - 17.274) + (333.169 - 25.945) )/ 2 )
=-177.534/( (257.668+307.224)/ 2 )
=-177.534/282.446
=-62.86 %

ArriVent BioPharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-184.444/( ( (333.169 - 25.945) + (349.295 - 24.995) )/ 2 )
=-184.444/( ( 307.224 + 324.3 )/ 2 )
=-184.444/315.762
=-58.41 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -58.41% mean?
ArriVent BioPharma (AVBP) has a ROCE % of -58.41% as of Mar. 2026.
Is ArriVent BioPharma's ROCE % too high?
ArriVent BioPharma's current ROCE % is -58.41%. Overall, ArriVent BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does ArriVent BioPharma's ROCE % compare to MAZE and DMRA?
ArriVent BioPharma's ROCE % of -58.41% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. ArriVent BioPharma's current ROCE % is -58.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArriVent BioPharma stock overvalued right now?
ArriVent BioPharma (AVBP) has a current ROCE % of -58.41%. The current ROCE % is -58.41%. ArriVent BioPharma's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ArriVent BioPharma (AVBP), the current ROCE % is -58.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ArriVent BioPharma Business Description

Address 18 Campus Boulevard, Suite 100, Newtown Square, PA, USA, 19073
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
12GF Score

Get the complete analysis for AVBP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.54
Price